1
|
Canella A, Nieves HC, Sborov DW, Cascione L, Radomska HS, Smith E, Stiff A, Consiglio J, Caserta E, Rizzotto L, Zanesi N, Stefano V, Kaur B, Mo X, Byrd JC, Efebera YA, Hofmeister CC, Pichiorri F. Correction: HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide. Oncotarget 2023; 14:837-838. [PMID: 37747363 PMCID: PMC10519243 DOI: 10.18632/oncotarget.28515] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/26/2023] Open
Affiliation(s)
- Alessandro Canella
- Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
- These authors have contributed equally to this work
| | - Hector Cordero Nieves
- Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
- These authors have contributed equally to this work
| | - Douglas W. Sborov
- Department of Internal Medicine, Oncology/Hematology Fellowship, The Ohio State University, Columbus, OH, USA
| | - Luciano Cascione
- Lymphoma and Genomics Research Program, IOR Institute of Oncology Research, Bellinzona, Switzerland
| | - Hanna S. Radomska
- Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
| | - Emily Smith
- Department of Internal Medicine, Biomedical Sciences Graduate Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
| | - Andrew Stiff
- Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
| | - Jessica Consiglio
- Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
- Present Address: Sanford Burnham Prebys Medical Discovery Insitute, La Jolla, CA, USA
| | - Enrico Caserta
- Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
| | - Lara Rizzotto
- Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
| | - Nicola Zanesi
- Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
| | - Volinia Stefano
- Department of Internal Medicine, Biosystems Analysis, LTTA, Department of Morphology, Surgery and Experimental Medicine, Università degli Studi, Ferrara, Italy
| | - Balveen Kaur
- Department of Neurological Surgery, Dardinger Laboratory for Neuro-oncology and Neurosciences, The Ohio State University Medical Center, Columbus, Ohio, USA
| | - Xiaokui Mo
- Department of Biomedical Informatics, Center for Biostatistics, The Ohio State University, Columbus, OH, USA
| | - John C. Byrd
- Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
- Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH, USA
| | - Yvonne A. Efebera
- Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH, USA
| | - Craig C. Hofmeister
- Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH, USA
| | - Flavia Pichiorri
- Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
- Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH, USA
| |
Collapse
|
2
|
Schnegg B, Muster C, Wieser M, Pavlicek-Bahlo M, Wiedermann S, Dobner S, Bruno J, Capek L, Potratz P, Jenni H, Sidler D, Chanias I, Daskalakis M, Consiglio J, Schwitz F, Thomet C, Schwerzmann M, Immer F, Longnus S, Martinelli M, Hunziker L, Siepe M, Reineke D. From Vpra of 100% to Transplantation, Journey of the First Ocs-dbd Case in Switzerland. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.491] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
3
|
Sapienza MR, Benvenuto G, Ferracin M, Mazzara S, Fuligni F, Tripodo C, Belmonte B, Fanoni D, Melle F, Motta G, Tabanelli V, Consiglio J, Mazzara V, Del Corvo M, Fiori S, Pileri A, Dellino GI, Cerroni L, Facchetti F, Berti E, Sabattini E, Paulli M, Croce CM, Pileri SA. Newly-Discovered Neural Features Expand the Pathobiological Knowledge of Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancers (Basel) 2021; 13:cancers13184680. [PMID: 34572907 PMCID: PMC8469149 DOI: 10.3390/cancers13184680] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2021] [Revised: 09/02/2021] [Accepted: 09/15/2021] [Indexed: 12/11/2022] Open
Abstract
Simple Summary For the first time, neuronal features are described in blastic plasmacytoid dendritic cell neoplasm (BPDCN) by a complex array of molecular techniques, including microRNA and gene expression profiling, RNA and Chromatin immunoprecipitation sequencing, and immunohistochemistry. The discovery of unexpected neural features in BPDCN may change our vision of this disease, leading to the designing of a new BPDCN cell model and to re-thinking the relations occurring between BPDCN and nervous system. The observed findings contribute to explaining the extreme tumor aggressiveness and also to propose novel therapeutic targets. In view of this, the identification, in this work of new potential neural metastatic inducers might open the way to therapeutic approaches for BPDCN patients based on the use of anti-neurogenic agents. Abstract Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and highly aggressive hematologic malignancy originating from plasmacytoid dendritic cells (pDCs). The microRNA expression profile of BPDCN was compared to that of normal pDCs and the impact of miRNA dysregulation on the BPDCN transcriptional program was assessed. MiRNA and gene expression profiling data were integrated to obtain the BPDCN miRNA-regulatory network. The biological process mainly dysregulated by this network was predicted to be neurogenesis, a phenomenon raising growing interest in solid tumors. Neurogenesis was explored in BPDCN by querying different molecular sources (RNA sequencing, Chromatin immunoprecipitation-sequencing, and immunohistochemistry). It was shown that BPDCN cells upregulated neural mitogen genes possibly critical for tumor dissemination, expressed neuronal progenitor markers involved in cell migration, exchanged acetylcholine neurotransmitter, and overexpressed multiple neural receptors that may stimulate tumor proliferation, migration and cross-talk with the nervous system. Most neural genes upregulated in BPDCN are currently investigated as therapeutic targets.
Collapse
Affiliation(s)
- Maria Rosaria Sapienza
- Division of Haematopathology, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy; (S.M.); (F.M.); (G.M.); (V.T.); (V.M.); (M.D.C.); (S.F.)
- Correspondence: (M.R.S.); (S.A.P.)
| | | | - Manuela Ferracin
- Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, 40138 Bologna, Italy; (M.F.); (A.P.)
| | - Saveria Mazzara
- Division of Haematopathology, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy; (S.M.); (F.M.); (G.M.); (V.T.); (V.M.); (M.D.C.); (S.F.)
| | - Fabio Fuligni
- Department of Genetics and Genome Biology, The Hospital for Sick Children, Toronto, ON M5G 0A4, Canada;
| | - Claudio Tripodo
- Tumor Immunology Unit, Human Pathology Section, Department of Health Science, Palermo University School of Medicine, 90134 Palermo, Italy; (C.T.); (B.B.)
| | - Beatrice Belmonte
- Tumor Immunology Unit, Human Pathology Section, Department of Health Science, Palermo University School of Medicine, 90134 Palermo, Italy; (C.T.); (B.B.)
| | - Daniele Fanoni
- Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, Italy; (D.F.); (E.B.)
| | - Federica Melle
- Division of Haematopathology, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy; (S.M.); (F.M.); (G.M.); (V.T.); (V.M.); (M.D.C.); (S.F.)
| | - Giovanna Motta
- Division of Haematopathology, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy; (S.M.); (F.M.); (G.M.); (V.T.); (V.M.); (M.D.C.); (S.F.)
| | - Valentina Tabanelli
- Division of Haematopathology, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy; (S.M.); (F.M.); (G.M.); (V.T.); (V.M.); (M.D.C.); (S.F.)
| | - Jessica Consiglio
- Department of Molecular Virology, Immunology and Medical Genetics, Ohio State University, Columbus, OH 43210, USA; (J.C.); (C.M.C.)
| | - Vincenzo Mazzara
- Division of Haematopathology, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy; (S.M.); (F.M.); (G.M.); (V.T.); (V.M.); (M.D.C.); (S.F.)
| | - Marcello Del Corvo
- Division of Haematopathology, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy; (S.M.); (F.M.); (G.M.); (V.T.); (V.M.); (M.D.C.); (S.F.)
| | - Stefano Fiori
- Division of Haematopathology, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy; (S.M.); (F.M.); (G.M.); (V.T.); (V.M.); (M.D.C.); (S.F.)
| | - Alessandro Pileri
- Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, 40138 Bologna, Italy; (M.F.); (A.P.)
| | - Gaetano Ivan Dellino
- Department of Experimental Oncology, European Institute of Oncology, 20141 Milan, Italy;
| | - Lorenzo Cerroni
- Die Dermatopathologie der Universitätsklinik für Dermatologie und Venerologie, LKH-Univ. Klinikum Graz, 8036 Graz, Austria;
| | - Fabio Facchetti
- Pathology Section, Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy;
| | - Emilio Berti
- Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, Italy; (D.F.); (E.B.)
- Department of Dermatology, Fondazione IRCCS Ca’ Granda-Ospedale Maggiore Policlinic and Milan University, 20122 Milan, Italy
| | - Elena Sabattini
- Haematopathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy;
| | - Marco Paulli
- Unit of Anatomic Pathology, Department of Molecular Medicine, University of Pavia and Fondazione IRCCS San Matteo Polyclinic, 27100 Pavia, Italy;
| | - Carlo Maria Croce
- Department of Molecular Virology, Immunology and Medical Genetics, Ohio State University, Columbus, OH 43210, USA; (J.C.); (C.M.C.)
| | - Stefano A. Pileri
- Division of Haematopathology, IEO, European Institute of Oncology IRCCS, 20141 Milan, Italy; (S.M.); (F.M.); (G.M.); (V.T.); (V.M.); (M.D.C.); (S.F.)
- Correspondence: (M.R.S.); (S.A.P.)
| |
Collapse
|
4
|
Pichiorri F, Palmieri D, De Luca L, Consiglio J, You J, Rocci A, Talabere T, Piovan C, Lagana A, Cascione L, Guan J, Gasparini P, Balatti V, Nuovo G, Coppola V, Hofmeister CC, Marcucci G, Byrd JC, Volinia S, Shapiro CL, Freitas MA, Croce CM. Correction: In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation. J Exp Med 2017; 214:1557. [PMID: 28104811 PMCID: PMC5413319 DOI: 10.1084/jem.2012095001172017c] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
5
|
Piccaluga PP, Navari M, De Falco G, Ambrosio MR, Lazzi S, Fuligni F, Bellan C, Rossi M, Sapienza MR, Laginestra MA, Etebari M, Rogena EA, Tumwine L, Tripodo C, Gibellini D, Consiglio J, Croce CM, Pileri SA, Leoncini L. Virus-encoded microRNA contributes to the molecular profile of EBV-positive Burkitt lymphomas. Oncotarget 2016; 7:224-40. [PMID: 26325594 PMCID: PMC4807994 DOI: 10.18632/oncotarget.4399] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2015] [Accepted: 07/20/2015] [Indexed: 01/28/2023] Open
Abstract
Burkitt lymphoma (BL) is an aggressive neoplasm characterized by consistent morphology and phenotype, typical clinical behavior and distinctive molecular profile. The latter is mostly driven by the MYC over-expression associated with the characteristic translocation (8;14) (q24; q32) or with variant lesions. Additional genetic events can contribute to Burkitt Lymphoma pathobiology and retain clinical significance. A pathogenetic role for Epstein-Barr virus infection in Burkitt lymphomagenesis has been suggested; however, the exact function of the virus is largely unknown. In this study, we investigated the molecular profiles (genes and microRNAs) of Epstein-Barr virus-positive and -negative BL, to identify specific patterns relying on the differential expression and role of Epstein-Barr virus-encoded microRNAs. First, we found significant differences in the expression of viral microRNAs and in selected target genes. Among others, we identified LIN28B, CGNL1, GCET2, MRAS, PLCD4, SEL1L, SXX1, and the tyrosine kinases encoding STK10/STK33, all provided with potential pathogenetic significance. GCET2, also validated by immunohistochemistry, appeared to be a useful marker for distinguishing EBV-positive and EBV-negative cases. Further, we provided solid evidences that the EBV-encoded microRNAs (e.g. BART6) significantly mold the transcriptional landscape of Burkitt Lymphoma clones. In conclusion, our data indicated significant differences in the transcriptional profiles of EBV-positive and EBV-negative BL and highlight the role of virus encoded miRNA.
Collapse
Affiliation(s)
- Pier Paolo Piccaluga
- Hematopathology Section, Department of Experimental, Diagnostic, and Experimental Medicine, S. Orsola-Malpighi Hospital, Bologna University School of Medicine, Bologna, Italy
| | - Mohsen Navari
- Hematopathology Section, Department of Experimental, Diagnostic, and Experimental Medicine, S. Orsola-Malpighi Hospital, Bologna University School of Medicine, Bologna, Italy.,Department of Medical Biotechnology, University of Siena, Siena, Italy
| | - Giulia De Falco
- Department of Medical Biotechnology, University of Siena, Siena, Italy.,School of Biological and Chemical Sciences, Queen Mary University of London, London, UK
| | | | - Stefano Lazzi
- Department of Medical Biotechnology, University of Siena, Siena, Italy
| | - Fabio Fuligni
- Hematopathology Section, Department of Experimental, Diagnostic, and Experimental Medicine, S. Orsola-Malpighi Hospital, Bologna University School of Medicine, Bologna, Italy
| | - Cristiana Bellan
- Department of Medical Biotechnology, University of Siena, Siena, Italy
| | - Maura Rossi
- Hematopathology Section, Department of Experimental, Diagnostic, and Experimental Medicine, S. Orsola-Malpighi Hospital, Bologna University School of Medicine, Bologna, Italy
| | - Maria Rosaria Sapienza
- Hematopathology Section, Department of Experimental, Diagnostic, and Experimental Medicine, S. Orsola-Malpighi Hospital, Bologna University School of Medicine, Bologna, Italy
| | - Maria Antonella Laginestra
- Hematopathology Section, Department of Experimental, Diagnostic, and Experimental Medicine, S. Orsola-Malpighi Hospital, Bologna University School of Medicine, Bologna, Italy
| | - Maryam Etebari
- Hematopathology Section, Department of Experimental, Diagnostic, and Experimental Medicine, S. Orsola-Malpighi Hospital, Bologna University School of Medicine, Bologna, Italy
| | - Emily A Rogena
- Department of Pathology, University of Nairobi, Nairobi, Kenya
| | | | - Claudio Tripodo
- Tumour Immunology Unit, Department of Health Science, Human Pathology Section, Palermo University School of Medicine, Palermo, Italy
| | - Davide Gibellini
- Department of Pathology and Diagnostic, University of Verona, Verona, Italy
| | - Jessica Consiglio
- Department of Molecular Virology, Immunology, and Medical Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
| | - Carlo M Croce
- Department of Molecular Virology, Immunology, and Medical Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
| | - Stefano A Pileri
- Diagnostic Hematopathology Unit, European Institute of Oncology, Milan, Italy
| | - Lorenzo Leoncini
- Department of Medical Biotechnology, University of Siena, Siena, Italy
| |
Collapse
|
6
|
Canella A, Cordero Nieves H, Sborov DW, Cascione L, Radomska HS, Smith E, Stiff A, Consiglio J, Caserta E, Rizzotto L, Zanesi N, Stefano V, Kaur B, Mo X, Byrd JC, Efebera YA, Hofmeister CC, Pichiorri F. HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide. Oncotarget 2016; 6:31134-50. [PMID: 26429859 PMCID: PMC4741593 DOI: 10.18632/oncotarget.5290] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2015] [Accepted: 09/14/2015] [Indexed: 12/25/2022] Open
Abstract
Multiple myeloma (MM) is a hematological malignancy of plasma cells in the bone marrow. Despite multiple treatment options, MM is inevitably associated with drug resistance and poor outcomes. Histone deacetylase inhibitors (HDACi's) are promising novel chemotherapeutics undergoing evaluation in clinical trials for the potential treatment of patients with MM. Although in preclinical studies HDACi's have proven anti-myeloma activity, but in the clinic single-agent HDACi treatments have been limited due to low tolerability. Improved clinical outcomes were reported only when HDACi's were combined with other drugs. Here, we show that a novel pan-HDACi AR-42 downregulates CD44, a glycoprotein that has been associated with lenalidomide and dexamethasone resistance in myeloma both in vitro and in vivo. We also show that this CD44 downregulation is in part mediated by miR-9–5p, targeting insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3), which directly binds to CD44 mRNA and increases its stability. Importantly, we also demonstrate that AR-42 enhances anti-myeloma activity of lenalidomide in primary MM cells isolated from lenalidomide resistant patients and in in vivo MM mouse model. Thus, our findings shed light on potential novel combinatorial therapeutic approaches modulating CD44 expression, which may help overcome lenalidomide resistance in myeloma patients.
Collapse
Affiliation(s)
- Alessandro Canella
- Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
| | - Hector Cordero Nieves
- Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
| | - Douglas W Sborov
- Department of Internal Medicine, Oncology/Hematology Fellowship, The Ohio State University, Columbus, OH, USA
| | - Luciano Cascione
- Lymphoma & Genomics Research Program, IOR Institute of Oncology Research, Bellinzona, Switzerland
| | - Hanna S Radomska
- Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
| | - Emily Smith
- Department of Internal Medicine, Biomedical Sciences Graduate Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
| | - Andrew Stiff
- Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
| | - Jessica Consiglio
- Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.,Present Address: Sanford Burnham Prebys Medical Discovery Insitute, La Jolla, CA, USA
| | - Enrico Caserta
- Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
| | - Lara Rizzotto
- Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
| | - Nicola Zanesi
- Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
| | - Volinia Stefano
- Department of Internal Medicine, Biosystems Analysis, LTTA, Department of Morphology, Surgery and Experimental Medicine, Università degli Studi, Ferrara, Italy
| | - Balveen Kaur
- Department of Neurological Surgery, Dardinger Laboratory for Neuro-oncology and Neurosciences, The Ohio State University Medical Center, Columbus, Ohio, USA
| | - Xiaokui Mo
- Department of Biomedical Informatics, Center for Biostatistics, The Ohio State University, Columbus, OH, USA
| | - John C Byrd
- Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.,Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH, USA
| | - Yvonne A Efebera
- Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH, USA
| | - Craig C Hofmeister
- Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH, USA
| | - Flavia Pichiorri
- Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.,Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH, USA
| |
Collapse
|
7
|
Palmieri D, Richmond T, Piovan C, Sheetz T, Zanesi N, Troise F, James C, Wernicke D, Nyei F, Gordon TJ, Consiglio J, Salvatore F, Coppola V, Pichiorri F, De Lorenzo C, Croce CM. Human anti-nucleolin recombinant immunoagent for cancer therapy. Proc Natl Acad Sci U S A 2015; 112:9418-23. [PMID: 26170308 PMCID: PMC4522807 DOI: 10.1073/pnas.1507087112] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
Nucleolin (NCL) is a nucleocytoplasmic protein involved in many biological processes, such as ribosomal assembly, rRNA processing, and mRNA stabilization. NCL also regulates the biogenesis of specific microRNAs (miRNAs) involved in tumor development and aggressiveness. Interestingly, NCL is expressed on the surface of actively proliferating cancer cells, but not on their normal counterparts. Therefore, NCL is an attractive target for antineoplastic treatments. Taking advantage of phage-display technology, we engineered a fully human single-chain fragment variable, named 4LB5. This immunoagent binds NCL on the cell surface, it is translocated into the cytoplasm of target cells, and it abrogates the biogenesis of NCL-dependent miRNAs. Binding of 4LB5 to NCL on the cell surface of a variety of breast cancer and hepatocellular carcinoma cell lines, but not to normal-like MCF-10a breast cells, dramatically reduces cancer cell viability and proliferation. Finally, in orthotopic breast cancer mouse models, 4LB5 administration results in a significant reduction of the tumor volume without evident side effects. In summary, here we describe, to our knowledge, the first anti-NCL single-chain fragment variable displaying antineoplastic activity against established solid tumors, which could represent the prototype of novel immune-based NCL-targeting drugs with clinical potential as diagnostic and therapeutic tools in a wide variety of human cancers.
Collapse
Affiliation(s)
- Dario Palmieri
- Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, OH 43210
| | - Timothy Richmond
- Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, OH 43210
| | - Claudia Piovan
- Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, OH 43210
| | - Tyler Sheetz
- Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, OH 43210
| | - Nicola Zanesi
- Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, OH 43210
| | - Fulvia Troise
- Centro di Ingegneria Genetica (CEINGE) Biotecnologie Avanzate, 80145 Naples, Italy
| | - Cindy James
- Department of Mass Spectroscopy and Proteomics, The Ohio State University, Columbus, OH 43210
| | - Dorothee Wernicke
- Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, OH 43210
| | - Fata Nyei
- Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, OH 43210
| | - Timothy J Gordon
- Department of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210
| | - Jessica Consiglio
- Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, OH 43210
| | - Francesco Salvatore
- Centro di Ingegneria Genetica (CEINGE) Biotecnologie Avanzate, 80145 Naples, Italy
| | - Vincenzo Coppola
- Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, OH 43210
| | - Flavia Pichiorri
- Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH 43210
| | - Claudia De Lorenzo
- Centro di Ingegneria Genetica (CEINGE) Biotecnologie Avanzate, 80145 Naples, Italy; Department of Molecular Medicine and Medical Biotechnologies, University of Napoli "Federico II", 80131 Naples, Italy
| | - Carlo M Croce
- Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, OH 43210;
| |
Collapse
|
8
|
Rocci A, Hofmeister CC, Geyer S, Stiff A, Gambella M, Cascione L, Guan J, Benson DM, Efebera YA, Talabere T, Dirisala V, Smith EM, Omedè P, Isaia G, De Luca L, Rossi D, Gentili S, Uccello G, Consiglio J, Ria R, Benevolo G, Bringhen S, Callea V, Weiss B, Ferro A, Magarotto V, Alder H, Byrd JC, Boccadoro M, Marcucci G, Palumbo A, Pichiorri F. Circulating miRNA markers show promise as new prognosticators for multiple myeloma. Leukemia 2014; 28:1922-6. [PMID: 24813918 PMCID: PMC4155011 DOI: 10.1038/leu.2014.155] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Affiliation(s)
- A Rocci
- Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy
| | - C C Hofmeister
- Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
| | - S Geyer
- Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
| | - A Stiff
- Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
| | - M Gambella
- Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy
| | - L Cascione
- 1] Molecular Virology, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA [2] Lymphoma & Genomics Research Program, Institute of Oncology Research-IOR, Bellinzona, Switzerland
| | - J Guan
- Molecular Virology, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
| | - D M Benson
- Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
| | - Y A Efebera
- Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
| | - T Talabere
- Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
| | - V Dirisala
- Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
| | - E M Smith
- Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
| | - P Omedè
- Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy
| | - G Isaia
- Department of Clinical and Biological Sciences, Division of Geriatric, S. Luigi Gonzaga Hospital, University of Torino, Torino, Italy
| | - L De Luca
- Laboratory of Preclinical and Translational Research, IRCCS-Referral Cancer Center of Basilicata (CROB), Rionero in Vulture, Italy
| | - D Rossi
- Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
| | - S Gentili
- Italian Multiple Myeloma Network, GIMEMA, Italy
| | - G Uccello
- Italian Multiple Myeloma Network, GIMEMA, Italy
| | - J Consiglio
- Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
| | - R Ria
- Italian Multiple Myeloma Network, GIMEMA, Italy
| | - G Benevolo
- Italian Multiple Myeloma Network, GIMEMA, Italy
| | - S Bringhen
- Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy
| | - V Callea
- Italian Multiple Myeloma Network, GIMEMA, Italy
| | - B Weiss
- Abramson Cancer Center, Division of Hematology-Oncology, University of Pennsylvania, Philadelphia, PA, USA
| | - A Ferro
- Department of Clinical and Molecular Biomedicine, University of Catania, Catania, Italy
| | - V Magarotto
- Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy
| | - H Alder
- Molecular Virology, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
| | - J C Byrd
- Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
| | - M Boccadoro
- Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
| | - G Marcucci
- Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy
| | - A Palumbo
- Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy
| | - F Pichiorri
- Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
| |
Collapse
|
9
|
Pichiorri F, Palmieri D, De Luca L, Consiglio J, You J, Rocci A, Talabere T, Piovan C, Lagana A, Cascione L, Guan J, Gasparini P, Balatti V, Nuovo G, Coppola V, Hofmeister CC, Marcucci G, Byrd JC, Volinia S, Shapiro CL, Freitas MA, Croce CM. In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation. J Exp Med 2013; 210:951-68. [PMID: 23610125 PMCID: PMC3646490 DOI: 10.1084/jem.20120950] [Citation(s) in RCA: 109] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2012] [Accepted: 03/22/2013] [Indexed: 11/11/2022] Open
Abstract
Numerous studies have described the altered expression and the causal role of microRNAs (miRNAs) in human cancer. However, to date, efforts to modulate miRNA levels for therapeutic purposes have been challenging to implement. Here we find that nucleolin (NCL), a major nucleolar protein, posttranscriptionally regulates the expression of a specific subset of miRNAs, including miR-21, miR-221, miR-222, and miR-103, that are causally involved in breast cancer initiation, progression, and drug resistance. We also show that NCL is commonly overexpressed in human breast tumors and that its expression correlates with that of NCL-dependent miRNAs. Finally, inhibition of NCL using guanosine-rich aptamers reduces the levels of NCL-dependent miRNAs and their target genes, thus reducing breast cancer cell aggressiveness both in vitro and in vivo. These findings illuminate a path to novel therapeutic approaches based on NCL-targeting aptamers for the modulation of miRNA expression in the treatment of breast cancer.
Collapse
Affiliation(s)
- Flavia Pichiorri
- Division of Hematology and Division of Oncology, Department of Internal Medicine; and Department of Molecular Virology, Immunology, and Medical Genetics; College of Medicine; and Comprehensive Cancer Center; The Ohio State University, Columbus, OH 43210
| | - Dario Palmieri
- Division of Hematology and Division of Oncology, Department of Internal Medicine; and Department of Molecular Virology, Immunology, and Medical Genetics; College of Medicine; and Comprehensive Cancer Center; The Ohio State University, Columbus, OH 43210
| | - Luciana De Luca
- Laboratorio di ricerca pre-clinica/traslazionale, Istituto di Ricovero e Cura a Carattere Scientifico Centro di Riferimento Oncologico della Basilicata, 85028 Rionero in Vulture (PZ), Italy
| | - Jessica Consiglio
- Division of Hematology and Division of Oncology, Department of Internal Medicine; and Department of Molecular Virology, Immunology, and Medical Genetics; College of Medicine; and Comprehensive Cancer Center; The Ohio State University, Columbus, OH 43210
| | - Jia You
- Division of Hematology and Division of Oncology, Department of Internal Medicine; and Department of Molecular Virology, Immunology, and Medical Genetics; College of Medicine; and Comprehensive Cancer Center; The Ohio State University, Columbus, OH 43210
| | - Alberto Rocci
- Division of Hematology and Division of Oncology, Department of Internal Medicine; and Department of Molecular Virology, Immunology, and Medical Genetics; College of Medicine; and Comprehensive Cancer Center; The Ohio State University, Columbus, OH 43210
- Divisione di Ematologia, Università di Torino, Azienda Ospedaliero Universitaria San Giovanni Battista, 10149 Turin, Italy
| | - Tiffany Talabere
- Division of Hematology and Division of Oncology, Department of Internal Medicine; and Department of Molecular Virology, Immunology, and Medical Genetics; College of Medicine; and Comprehensive Cancer Center; The Ohio State University, Columbus, OH 43210
| | - Claudia Piovan
- Division of Hematology and Division of Oncology, Department of Internal Medicine; and Department of Molecular Virology, Immunology, and Medical Genetics; College of Medicine; and Comprehensive Cancer Center; The Ohio State University, Columbus, OH 43210
- Start-Up Unit, Department of Experimental Oncology, Tumor National Institute, 20133 Milan, Italy
| | - Alessandro Lagana
- Division of Hematology and Division of Oncology, Department of Internal Medicine; and Department of Molecular Virology, Immunology, and Medical Genetics; College of Medicine; and Comprehensive Cancer Center; The Ohio State University, Columbus, OH 43210
| | - Luciano Cascione
- Division of Hematology and Division of Oncology, Department of Internal Medicine; and Department of Molecular Virology, Immunology, and Medical Genetics; College of Medicine; and Comprehensive Cancer Center; The Ohio State University, Columbus, OH 43210
- Department of Clinical and Molecular Biomedicine, University of Catania, 95122 Catania, Italy
| | - Jingwen Guan
- Division of Hematology and Division of Oncology, Department of Internal Medicine; and Department of Molecular Virology, Immunology, and Medical Genetics; College of Medicine; and Comprehensive Cancer Center; The Ohio State University, Columbus, OH 43210
| | - Pierluigi Gasparini
- Division of Hematology and Division of Oncology, Department of Internal Medicine; and Department of Molecular Virology, Immunology, and Medical Genetics; College of Medicine; and Comprehensive Cancer Center; The Ohio State University, Columbus, OH 43210
| | - Veronica Balatti
- Division of Hematology and Division of Oncology, Department of Internal Medicine; and Department of Molecular Virology, Immunology, and Medical Genetics; College of Medicine; and Comprehensive Cancer Center; The Ohio State University, Columbus, OH 43210
| | - Gerard Nuovo
- Division of Hematology and Division of Oncology, Department of Internal Medicine; and Department of Molecular Virology, Immunology, and Medical Genetics; College of Medicine; and Comprehensive Cancer Center; The Ohio State University, Columbus, OH 43210
- Phylogeny Inc., Powell, OH 43065
| | - Vincenzo Coppola
- Division of Hematology and Division of Oncology, Department of Internal Medicine; and Department of Molecular Virology, Immunology, and Medical Genetics; College of Medicine; and Comprehensive Cancer Center; The Ohio State University, Columbus, OH 43210
| | - Craig C. Hofmeister
- Division of Hematology and Division of Oncology, Department of Internal Medicine; and Department of Molecular Virology, Immunology, and Medical Genetics; College of Medicine; and Comprehensive Cancer Center; The Ohio State University, Columbus, OH 43210
| | - Guido Marcucci
- Division of Hematology and Division of Oncology, Department of Internal Medicine; and Department of Molecular Virology, Immunology, and Medical Genetics; College of Medicine; and Comprehensive Cancer Center; The Ohio State University, Columbus, OH 43210
| | - John C. Byrd
- Division of Hematology and Division of Oncology, Department of Internal Medicine; and Department of Molecular Virology, Immunology, and Medical Genetics; College of Medicine; and Comprehensive Cancer Center; The Ohio State University, Columbus, OH 43210
| | - Stefano Volinia
- Division of Hematology and Division of Oncology, Department of Internal Medicine; and Department of Molecular Virology, Immunology, and Medical Genetics; College of Medicine; and Comprehensive Cancer Center; The Ohio State University, Columbus, OH 43210
- Data Mining for Analysis of Microarrays, Department of Morphology and Embryology, University of Ferrara, 44100 Ferrara, Italy
| | - Charles L. Shapiro
- Division of Hematology and Division of Oncology, Department of Internal Medicine; and Department of Molecular Virology, Immunology, and Medical Genetics; College of Medicine; and Comprehensive Cancer Center; The Ohio State University, Columbus, OH 43210
| | - Michael A. Freitas
- Division of Hematology and Division of Oncology, Department of Internal Medicine; and Department of Molecular Virology, Immunology, and Medical Genetics; College of Medicine; and Comprehensive Cancer Center; The Ohio State University, Columbus, OH 43210
| | - Carlo M. Croce
- Division of Hematology and Division of Oncology, Department of Internal Medicine; and Department of Molecular Virology, Immunology, and Medical Genetics; College of Medicine; and Comprehensive Cancer Center; The Ohio State University, Columbus, OH 43210
| |
Collapse
|
10
|
Pichiorri F, Palmieri D, Luca LD, Consiglio J, You J, Rocci A, Talabere T, Piovan C, Lagana A, Cascione L, Guan J, Gasparini P, Balatti V, Nuovo G, Coppola V, Hofmeister CC, Marcucci G, Byrd JC, Volinia S, Shapiro CL, Freitas MA, Croce CM. In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation. J Biophys Biochem Cytol 2013. [DOI: 10.1083/jcb2013oia4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
11
|
Palmieri D, De Luca L, Consiglio J, Rocci A, Talabere T, Piovan C, Lagana A, Cascione L, Guan J, Gasparini P, Balatti V, Coppola V, Hofmeister C, Marcucci G, Byrd J, Volinia S, Shapiro C, Freitas M, Croce C, Pichiorri F. Abstract 1122: In vivo NCL-targeting affects breast cancer aggressiveness through miRNA regulation. Cancer Res 2013. [DOI: 10.1158/1538-7445.am2013-1122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
MicroRNAs (miRNAs) are noncoding single-stranded RNA molecules of ∼22 nucleotides in length. They have a critical role in regulating gene expression by targeting messenger RNAs (mRNAs) in a sequence-specific manner. Active mature miRNAs are produced from primary miRNA transcripts (pri-miRNAs) through sequential cleavages by the microprocessor complex, which includes DROSHA, DGCR8, and DICER proteins. Several miRNAs are specifically up-regulated in various types of tumors, and a wide range of studies have demonstrated how their down-regulation could potentially affect tumorigenesis, metastasis formation and drug resistance. However, most of these studies have indicated the possibility of modulating miRNA expression at the transcriptional level, while only a few focused on post-transcriptional control. Nucleolin (NCL) is a highly conserved multifunctional protein involved in ribosomal RNA (rRNA) biogenesis and in the stabilization of different mRNAs, in the nucleus and in the cytoplasm of normal and cancer cells. NCL was also found on the surface of different types of cancer cells, but not on their normal counterparts, shuttling between the inner and the outer part of the cell membrane. These observations suggested that NCL might be considered a cancer cell specific receptor, able to mediate tumor-selective uptake of specific ligands such as RNA and DNA G-rich aptamers. Here we show that NCL binds the terminal loop and promotes the maturation of a specific set of miRNAs, including miR-21, miR-103, miR-221 and miR-222, whose over-expression is causally associated with greater aggressiveness and resistance to anti-neoplastic therapies of several kind of tumors, such as breast cancer. Accordingly, a direct correlation between the expression levels of NCL and NCL-dependent miRNAs in human breast cancer samples was also observed. Conversely, NCL impairment down-regulated NCL-dependent miRNAs and up-regulates their target in vitro, affecting cancer cell proliferation, migration and anti-neoplastic drug resistance. Finally, we used AS1411, the first NCL-targeting G-rich aptamer that has reached phase II clinical trials for cancer therapy, to inhibit NCL activity in orthotopc xenograft models of breast cancer. Our in vivo data demonstrate that AS1411 down-regulates NCL-dependent miRNAs, hindering breast cancer metastasis. These findings provide insights into the molecular function of NCL in miRNA biology, as well as one of the first realistic strategies for miRNA regulation in cancer therapy.
Citation Format: Dario Palmieri, Luciana De Luca, Jessica Consiglio, Alberto Rocci, Tiffany Talabere, Claudia Piovan, Alessandro Lagana, Luciano Cascione, Jingwen Guan, Pierluigi Gasparini, Veronica Balatti, Vincenzo Coppola, Craig Hofmeister, Guido Marcucci, John Byrd, Stefano Volinia, Charles Shapiro, Michael Freitas, Carlo Croce, Flavia Pichiorri. In vivo NCL-targeting affects breast cancer aggressiveness through miRNA regulation. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1122. doi:10.1158/1538-7445.AM2013-1122
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | - John Byrd
- 1The Ohio State University, Columbus, OH
| | | | | | | | | | | |
Collapse
|
12
|
Consiglio J, Luca LD, Acunzo M, Galasso M, Rocci A, Sapienza MR, Piccaluga PP, Vecchione A, Zanesi N, Volinia S, Croce CM, Pichiorri F. Abstract 5032: New insights of miR-221 and miR-222 cluster functions in Burkitt lymphoma. Cancer Res 2012. [DOI: 10.1158/1538-7445.am2012-5032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Burkitt lymphoma (BL) is a mature aggressive B-cell neoplasm, with a characteristic clinical presentation, morphology and immunophenotype. Several studies have indicated the importance of miRNAs in B cell maturation and in the development of B cell lymphomas. MicroRNAs (miRNA) are a class of naturally occurring, small, non-coding RNA that can control gene expression by targeting mRNA molecules for translational repression or cleavage. They are usually expressed in a tissue-specific manner and play important roles in apoptosis, differentiation and cell proliferation; therefore their deregulation may be involved in carcinogenesis or tumor progression by altering normal gene expression patterns. Over the past years microRNAs signatures have been described to characterize and classify different types of BL or to investigate the expression of miRNAs possibly regulated by c-Myc in BL cases positive or negative for Myc traslocation. Howhever, it remained unclear the functional role of miRNAs that have been found differentially expressed and no further studies have been conducted. We performed miRNA expression profile to gain further insights into the molecular pathology of BL. We conducted array analysis on a set of 5 sporadic BL patients, 3 endemic BL patients, 9 reactive tissues and 11 cases of mononucleosis. A common trend of miRNAs altered expression was also observed by NanoString analysis in 10 BL cell lines compared to 5 normal CD-19+ B cells. Among several miRNAs previously described be deregulated in BL we identified a severe down-regulation of miR-221, miR-222 in all classes of comparisons we analyzed. The down-regulation of miR-221 and miR-222 associated to BL has been also confirmed by q-RT-PCR method in a different cohort of BL patients (20) compared to the healthy controls (6). When miR-221 and miR-222 expressions have been restored in BL cancer cell lines, lacking of their expression, by gene expression profile we identified the differentially expression of several genes involved in ncRNAs processing, ncRNA metabolic process and also in the regulation of cell differentiation and cell cycle. Furthermore, functional experiments identified many of these genes as new direct targets of miR-221 and miR-222. In conclusion, our study reveals new insights into the functional significance in loss of miR-221 and miR-222 expression in BL pathogenesis.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 5032. doi:1538-7445.AM2012-5032
Collapse
Affiliation(s)
| | - Luciana De Luca
- 2Molecular Oncology Unit IRCCS, Referral Cancer Center of Basilicata-Crob, Pionero in Vulture (PZ), Potenza, Italy
| | | | - Marco Galasso
- 3DAMA, Department of Morphology and Embryology and Technopolo for Life Sciences, University of Ferrara, Ferrara, Italy
| | | | - Maria-Rosaria Sapienza
- 4Hematopathology Section, S-Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
| | - Pier Paolo Piccaluga
- 4Hematopathology Section, S-Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
| | | | | | | | | | | |
Collapse
|
13
|
Veronese A, Consiglio J, Visone R, Zanesi N, Ferracin M, Lanza G, Querzoli P, Angioni A, Croce C, Negrini M. Abstract 2087: miR-483-3p is an oncogene involved in nephroblastoma and in adult tumors with activated β-catenin. Cancer Res 2010. [DOI: 10.1158/1538-7445.am10-2087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The hsa-mir-483 locus is located within intron 2 of the IGF2 locus. Here, we show that the mature microRNA (miRNA) miR-483-3p is over-expressed and co-regulated with IGF2 in 100% of Wilms’ tumors. Additionally, several types of common adult cancers exhibit high or even extremely high levels of miR-483-3p. We show that the mutation status of the oncoprotein β-catenin is correlated with the expression of the miR-483-3p in hepatocarcinoma and colorectal cancer. These findings suggested an autonomous oncogenic function for this miRNA. Indeed, anti-microRNA oligonucleotide (AMO) against miR-483-3p could inhibit tumorigenicity of HepG2 cells. At the same time, no anti-tumor effect was elicited by inhibition of IGF2. The oncogenic properties of miR-483-3p were further supported by the finding that its ectopic expression could protect cells from apoptosis through the regulation of one important pro-apoptotic protein, Puma. Our results indicate that miR-483-3p can function as an anti-apoptotic oncogene in various human cancers and reveal a new potentially important target for anti-cancer therapy.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2087.
Collapse
|
14
|
Veronese A, Lupini L, Consiglio J, Visone R, Ferracin M, Fornari F, Zanesi N, Alder H, D'Elia G, Gramantieri L, Bolondi L, Lanza G, Querzoli P, Angioni A, Croce CM, Negrini M. Oncogenic role of miR-483-3p at the IGF2/483 locus. Cancer Res 2010; 70:3140-9. [PMID: 20388800 DOI: 10.1158/0008-5472.can-09-4456] [Citation(s) in RCA: 171] [Impact Index Per Article: 12.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
hsa-mir-483 is located within intron 2 of the IGF2 locus. We found that the mature microRNA (miRNA) miR-483-3p is overexpressed in 100% of Wilms' tumors. In addition, colon, breast, and liver cancers exhibit high or even extremely high levels of miR-483-3p in approximately 30% of the cases. A coregulation with IGF2 mRNA was detected, although some tumors exhibited high expression of miR-483-3p without a concomitant increase of IGF2. These findings suggested that miR-483-3p could cooperate with IGF2 or act as an autonomous oncogene. Indeed, here we prove that an anti-miRNA oligonucleotide against miR-483-3p could inhibit the miRNAs without affecting IGF2 mRNA and it could suppress tumorigenicity of HepG2 cells, a cell line that overexpresses miR-483-3p and IGF2. Conversely, no antitumor effect was elicited by inhibition of IGF2. The oncogenic mechanism of miR-483-3p was at least partially clarified by the finding that it could modulate the proapoptotic protein BBC3/PUMA and miR-483-3p enforced expression could protect cells from apoptosis. Our results indicate that miR-483-3p could function as an antiapoptotic oncogene in various human cancers and reveal a new, potentially important target for anticancer therapy.
Collapse
Affiliation(s)
- Angelo Veronese
- Dipartimento di Medicina Sperimentale e Diagnostica, Università di Ferrara, Ferrara, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|